PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers

Elena Castro

doi:10.1016/j.euf.2024.08.005

PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers

Eur Urol Focus. 2024 Jul;10(4):504-505. doi: 10.1016/j.euf.2024.08.005. Epub 2024 Sep 3.

Author

Elena Castro¹

Affiliation

¹ Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: [email protected].

PMID: 39232907
DOI: 10.1016/j.euf.2024.08.005

Abstract

For patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 alterations, the potential benefits of combining a PARP inhibitor and an androgen receptor pathway inhibitor for first-line treatment outweigh the potential side effects. Further research is required to identify patients without detectable BRCA1/2 defects who would benefit from this approach.

MeSH terms

Androgen Receptor Antagonists* / therapeutic use
BRCA1 Protein / genetics
BRCA2 Protein / genetics
Humans
Male
Mutation
Neoplasm Metastasis
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Prostatic Neoplasms, Castration-Resistant* / pathology
Receptors, Androgen / genetics

Substances

Poly(ADP-ribose) Polymerase Inhibitors
Androgen Receptor Antagonists
BRCA2 Protein
BRCA1 Protein
Receptors, Androgen
BRCA2 protein, human